{"nctId":"NCT01948830","briefTitle":"Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD","startDateStruct":{"date":"2013-12-17","type":"ACTUAL"},"conditions":["Age-related Macular Degeneration","Choroidal Neovascularization"],"count":650,"armGroups":[{"label":"Group I ranibizumab 0.5 mg monthly","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab 0.5mg"]},{"label":"Group II ranibizumab 0.5 mg TER","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab 0.5mg"]}],"interventions":[{"name":"Ranibizumab 0.5mg","otherNames":["Lucentis"]},{"name":"Ranibizumab 0.5mg","otherNames":["Lucentis"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female patients, ≥50 years of age with signed informed consent before study procedures\n* Visual impairment predominantly due to nAMD.\n* Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by fluorescein angiography (FA) and/or color fundus photography\n* Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT\n* BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate Snellen equivalent of 20/32 and 20/320)\n\nKey Exclusion Criteria:\n\n* Any type of advanced, severe or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.\n* Stroke or myocardial infarction within 3 months prior to Screening.\n* Any active periocular or ocular infection or inflammation in both eyes.\n* Ocular disorders in the study eye at the time of enrollment that may confound interpretation of study results and compromise visual acuity.\n* Presence of amblyopia or amaurosis in the fellow eye.\n* History of treatment with any anti-angiogenic drugs (including any anti- vascular endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab \\[Avastin®\\], aflibercept \\[Eylea®\\]) or vPDT in the study eye.\n* History of intravitreal treatment with corticosteroids within 6 months and history of intra-ocular surgery within 3 months in the study eye prior to the Screening.\n* Pregnant or nursing (lactating) women. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12","description":"Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"0.70"},{"groupId":"OG001","value":"8.1","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Number of Visits Scheduled","description":"The number of visits scheduled according to the treat and extend regimen after treatment initiation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"2.56"},{"groupId":"OG001","value":"11.2","spread":"2.37"}]}]}]},{"type":"SECONDARY","title":"Change in BCVA From Baseline to Month 12","description":"Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"14.11"},{"groupId":"OG001","value":"8.0","spread":"11.61"}]}]}]},{"type":"SECONDARY","title":"Average BCVA Change From Baseline to Month 12","description":"Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.\n\nMean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"10.50"},{"groupId":"OG001","value":"7.1","spread":"9.41"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12","description":"Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"7.56"},{"groupId":"OG001","value":"4.2","spread":"6.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"8.64"},{"groupId":"OG001","value":"5.8","spread":"8.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"9.09"},{"groupId":"OG001","value":"6.7","spread":"9.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"10.90"},{"groupId":"OG001","value":"7.3","spread":"9.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"11.34"},{"groupId":"OG001","value":"7.7","spread":"10.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"13.34"},{"groupId":"OG001","value":"7.9","spread":"10.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"14.25"},{"groupId":"OG001","value":"7.9","spread":"11.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"12.87"},{"groupId":"OG001","value":"7.9","spread":"11.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"13.63"},{"groupId":"OG001","value":"7.6","spread":"12.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"13.44"},{"groupId":"OG001","value":"7.6","spread":"12.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"14.12"},{"groupId":"OG001","value":"7.5","spread":"12.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"13.41"},{"groupId":"OG001","value":"7.9","spread":"11.96"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"233","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"249","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"238","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"196","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"230","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"222","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"226","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit","description":"Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"296","spread":null},{"groupId":"OG001","value":"295","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"313","spread":null},{"groupId":"OG001","value":"314","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"319","spread":null},{"groupId":"OG001","value":"320","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null},{"groupId":"OG001","value":"306","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"309","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"299","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"304","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"286","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"301","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"307","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"287","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"295","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"271","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"286","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"268","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"279","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"262","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"286","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"270","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"281","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"263","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"275","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":null},{"groupId":"OG001","value":"256","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"267","spread":null},{"groupId":"OG001","value":"272","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null},{"groupId":"OG001","value":"284","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12","description":"Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Number of Treatment Frequency","description":"The number of injections received","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"2.68"},{"groupId":"OG001","value":"11.0","spread":"2.50"}]}]}]},{"type":"SECONDARY","title":"The Average Number of Days Between Injections","description":"The average dosing interval was measured as the average number of days between injections","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":"11.28"},{"groupId":"OG001","value":"29.4","spread":"3.27"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Fluid Free Macula Over Time up to Month 12","description":"OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.5","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Central Subfield Retinal Thickness (CSFT) Over Time","description":"OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-137.6","spread":"132.33"},{"groupId":"OG001","value":"-126.8","spread":"119.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-151.6","spread":"151.15"},{"groupId":"OG001","value":"-149.2","spread":"137.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-149.8","spread":"167.26"},{"groupId":"OG001","value":"-151.8","spread":"149.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-141.8","spread":"183.71"},{"groupId":"OG001","value":"-161.3","spread":"149.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-138.6","spread":"160.04"},{"groupId":"OG001","value":"-160.9","spread":"148.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-140.1","spread":"156.25"},{"groupId":"OG001","value":"-163.4","spread":"157.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-146.6","spread":"160.72"},{"groupId":"OG001","value":"-166.9","spread":"161.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-153.4","spread":"151.93"},{"groupId":"OG001","value":"-170.4","spread":"156.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-150.2","spread":"153.82"},{"groupId":"OG001","value":"-169.3","spread":"156.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-154.6","spread":"162.77"},{"groupId":"OG001","value":"-170.9","spread":"153.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-133.1","spread":"170.47"},{"groupId":"OG001","value":"-174.8","spread":"163.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-172.1","spread":"162.81"},{"groupId":"OG001","value":"-173.3","spread":"154.13"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at","description":"To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)","description":"The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"13.93"},{"groupId":"OG001","value":"4","spread":"13.72"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":39,"n":323},"commonTop":["Intraocular pressure increased (Study eye)","Nasopharyngitis","Hypertension","Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Study eye)"]}}}